The Biosensor Using the Target Urine VOCs for Detecting DKD Diabetic Kidney Disease
Key facts
- Who runs it
- Suranaree University of Technology
- Where
- Thailand1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 12 May 2025
- Ended
- 13 May 2025
- Type of study
- Observational, 4 groups
- Treatments tested
- The Biosensor Using the Target Urine Volatile Organic Compounds
- Record updated
- 22 August 2025
- Why it stopped
- This record was initially withdrawn due to incomplete protocol section. The study was completed and published, and a corrected version will be submitted under a new record
Who can take part
- Age
- 20 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Age > 20 years
- In DKD and NS groups must undergone renal biopsy before study
Who cannot take part
- Patients with an estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m2
- Pregnancy
- Ambiguous pathological results
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Volatile organic compounds (VOCs) are easily evaporated substances produced by pathophysiologic metabolism and have been utilized in research as potential new biomarkers for differentiating various diseases, acting as the odor imprints of each disease.
Read full original descriptionShow less
Researchers used metal oxide semiconductors to examine the properties of VOCs produced by diabetic kidney disease patients. Also, the VOCs of those with diabetic kidney disease were then compared with those of healthy individuals and patients with nephrotic syndrome.
The study found that VOCs primarily composed of hydrogen, methanol, and sulfate in diabetic kidney disease patients had a significantly different ability to release free electrons from the metal oxide semiconductors compared to healthy individuals and patients with nephrotic syndrome from other causes. This finding suggested that VOCs could be used as biomarkers which could lead to the replacement of renal biopsy for diagnosis in the future.
The 4 groups in the trial
- 3
็Healthy volunteer, DKD pateints, other causes of Nephrotic syndrome
Treatment: The Biosensor Using the Target Urine Volatile Organic Compounds
- ็Healthy volunteer
็Healthy volunteer = normal subject or diabetes pateint without proteinuria (\< 300 mg/day)
Treatment: The Biosensor Using the Target Urine Volatile Organic Compounds
- DKD pateints
DKD = diabetic kidney disease with proteinuria (\> 1 g/day) with confirmed by pathological results
Treatment: The Biosensor Using the Target Urine Volatile Organic Compounds
- other causes of Nephrotic syndome
NS = other casues of nephrotic syndrome, pateints must have with proteinuria \> 3.5 g/day) with confirmed by pathological results. In addition, They must have no DM in the illness profile.
Treatment: The Biosensor Using the Target Urine Volatile Organic Compounds
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Biosensor Using the Target Urine Volatile Organic Compounds for Detecting Diabetic Kidney Disease
- Record updated
- 22 August 2025